Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEUS for Monitoring TACE Response in HCC
NCT02764801Phase 3Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Apr 2016
- Primary completion
- Dec 2021
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of perflutren lipid microspheres in hepatocellular carcinoma (HCC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Apr 2016; status: completed.
02
Drugs
perflutren lipid microspheres
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02764801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02764801.